Be Healthy Celebration Week at Lek, a Sandoz company
- Be Healthy Celebration Week is a core within the Novartis health and well-being Be Healthy initiative for the benefit of Novartis associates.
- This year, Lek, a Sandoz company, which has participated in the initiative from the very beginning, organises the Be Healthy Celebration Week at its sites for the third time in a row.
- Associates can take part in sports activities, attend lectures on healthy lifestyle or a first aid course, measure key health indicators and enjoy healthy meals.
More than 2,400 Lek employees participate in the Be Healthy Celebration Week 2013, a core five-day event within Novartis global Be Healthy initiative, intended for active promotion of healthy living among the associates. This year’s Be Healthy Celebration Week will take place in Slovenia from September 23-27 at all sites of Lek, a Sandoz company – in Ljubljana, Mengeš, Lendava and Prevalje.
The Be Healthy Celebration Week activities encompass all four pillars of the Be Healthy initiative (Move, Choose, Know, Manage) and thus contribute to a comprehensive approach to the health of associates. During the whole week, Lek’s associates can join organised sports activities, lectures and courses for healthier lifestyle during working hours.
They can learn the basic of Nordic walking, one of the healthiest ways of recreation where the whole body is active, with Petra Majdič, together with the only two Nordic walking technique instructors in Slovenia. The associates can attend a lecture on balanced diet and on managing stressful situations in the workplace held by Dr Nada Rotovnik Kozjek. They can measure their ankle-brachial index and have their tumour marker levels for detecting the presence of prostate cancer tested. The associates will also have an opportunity to take a first-aid refresher course conducted by the Ljubljana Medical Centre Rescue Station.
»Everybody takes care of his/her own health, however it is the responsibility of an employer to encourage the employees to embrace healthy lifestyles. Healthy and relaxed employees can cope more easily with challenges both at the workplace and in their private lives,« said Robert Hribar, Head HSE at Lek, a Sandoz member, on the occasion of the Be Healthy Celebration Week. »Therefore I am pleased that this year, movement, healthy eating and well-being activities have once again taken over Lek’s premises for a few days. The program is designed so as to enable a comprehensive approach to maintaining a healthy lifestyle of the associates. We focused particular attention on our associates in production and therefore adjusted the program of activities during the Be Health Celebration Week to their work schedule.«
About the Novartis global Be Healthy initiative
The health and well-being of associates is a top priority for the Novartis Group and a natural extension of the company purpose of “care and cure”. With this aim, three years ago Novartis launched the internal Be Health initiative order to help its associates to take an active role in taking care of their own health. The global Be Health initiative is dedicated to associates within all Novartis affiliates and runs throughout the year.
Novartis is focusing on prevention programs in Be Healthy because statistics from the World Economic Forum (WEF) show that workplace health and well-being programs addressing lifestyle changes can help prevent up to 40% of non-communicable diseases (NCDs) such as cardiovascular disease, cancer and lung disorders. The World Health organisation (WHO) recently set a global target to reduce NCDs by 25% by the year 2025, and Be Healthy is the contribution of Novartis toward this goal.
Be healthy has a broad reach within Novartis. At launch in 2011, 76 of the largest Novartis Group company sites across 32 countries were involved, reaching 80% of affiliates’ associates. In 2013, more than 176 sites across 50 countries are implementing Be Healthy and the program now reaches 95% of associates.
Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/eng/.
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the rapidly growing generics industry. Sandoz offers a broad range of about 1, 100 high-quality, affordable products that are no longer protected by patents. With nearly 26,000 employees in approximately 140 countries, Sandoz holds the #1 position globally in biosimilars, injectables, ophthalmics and dermatology as well as a strong global #5 position in inhalables. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments, and hormone therapies. Sandoz develops, produces, and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US). In 2012, Sandoz posted sales of USD 8.7 billion. For more information, please visit www.sandoz.com.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 128,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32